No Abstract BioWorld International CorrespondentSantaris Pharma A/S raised €20.4 million (US$29.4 million) in a new investment round led by Gilde Healthcare Partners BV, of Utrecht, the Netherlands, which contributed €7.5 million of the total. Read More
Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on a marketing authorization application for its lead drug, the hereditary angioedema treatment Rhucin. (BioWorld International) Read More
